Management of Alcohol Withdrawal Anxiety

Pharmacological Management

The American Association for the Study of Liver Diseases recommends benzodiazepines as the gold standard first-line treatment for alcohol withdrawal anxiety, with long-acting agents preferred for most patients, and lorazepam reserved for those with liver dysfunction, advanced age, or respiratory compromise 1, 2, 3.
Long-acting benzodiazepines, such as diazepam and chlordiazepoxide, are preferred for alcohol withdrawal anxiety because they provide superior protection against seizures and delirium tremens while simultaneously treating anxiety symptoms through GABA activation 1, 2, 3.
Diazepam is recommended at a dose of 5-10 mg PO/IV/IM every 6-8 hours 1.
Chlordiazepoxide is recommended at a dose of 25-100 mg PO every 4-6 hours 1.
Lorazepam is recommended for patients with severe liver dysfunction, advanced age, or respiratory compromise at a dose of 1-4 mg PO/IV/IM every 4-8 hours 3, 5.

The American College of Gastroenterology recommends thiamine supplementation for all patients with alcohol withdrawal to prevent Wernicke's encephalopathy, with a standard dosing of 100-300 mg/day orally 1, 5.
Thiamine should be maintained for 2-3 months following resolution of withdrawal symptoms 1.
High-risk patients, such as those with malnourishment or severe withdrawal, should receive parenteral thiamine 100-500 mg/day 1, 4.
Electrolyte correction, including magnesium deficiency, is recommended to prevent exacerbation of withdrawal symptoms 1, 5.

Inpatient management is required for patients with significant withdrawal symptoms, history of withdrawal seizures or delirium tremens, concurrent serious medical illness, or concurrent serious psychiatric disorders 1, 2, 4.
Outpatient management is appropriate for patients with mild to moderate withdrawal symptoms, no history of complicated withdrawal, adequate social support, and no serious medical or psychiatric comorbidities 1, 4.

Psychiatric consultation is strongly recommended for all patients with alcohol withdrawal syndrome to evaluate and manage withdrawal, plan for long-term abstinence, and assess comorbid psychiatric disorders 1, 4, 5.

Glucose-containing fluids should not be administered before thiamine to prevent precipitating acute thiamine deficiency and Wernicke's encephalopathy 1, 5.
Antipsychotics should not be used as monotherapy for withdrawal anxiety, as they increase seizure risk and should only be used as adjuncts to benzodiazepines for severe agitation or hallucinations not controlled by adequate benzodiazepine doses 1, 4.
Benzodiazepines should not be prescribed beyond 7-14 days to prevent iatrogenic dependence 4.

Patients can be safely discharged when they demonstrate stable vital signs, resolution of withdrawal symptoms, no complications requiring inpatient care, and a comprehensive follow-up plan in place 4.